NCT06948487 Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
| NCT ID | NCT06948487 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Condition | Gastritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2025-06-17 |
| Primary Completion | 2025-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,000 participants in total. It began in 2025-06-17 with a primary completion date of 2025-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Eligibility Criteria
Inclusion Criteria: * Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent. * Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication. * Subjects who present with at least one subjective symptom requiring medical treatment * Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data. Exclusion Criteria: * Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling. * Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Contact & Investigator
Jingun Kim, Dr.
PRINCIPAL INVESTIGATOR
Masong Kim Internal Medicine Clinic
Frequently Asked Questions
Who can join the NCT06948487 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 75 Years, studying Gastritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06948487 currently recruiting?
Yes, NCT06948487 is actively recruiting participants. Contact the research team at 2210325@daewoong.co.kr for enrollment information.
Where is the NCT06948487 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06948487 clinical trial?
NCT06948487 is sponsored by Daewoong Pharmaceutical Co. LTD.. The principal investigator is Jingun Kim, Dr. at Masong Kim Internal Medicine Clinic. The trial plans to enroll 12,000 participants.